Zacks Investment Research Upgrades Gilead Sciences, Inc. (NASDAQ:GILD) to "Buy"

Zacks Investment Research Upgrades Gilead Sciences, Inc. (NASDAQ:GILD) to "Buy"


The firm currently has a $79.00 price objective on the biopharmaceutical company's stock. Zacks Investment Research 's target price suggests a potential upside of 11.95% from the stock's previous close.



from Biotech News